Femasys Inc.

The company is a U.S. manufacturer and a biomedical innovator focused on women's health. It develops and commercializes therapeutic and diagnostic products globally, with regulatory approvals in the U.S. and key international markets. Its product portfolio includes FemaSeed Intratubal Insemination, a U.S. FDA-cleared and internationally approved infertility treatment available in Europe, the United Kingdom, Canada, Israel, Australia, and New Zealand. FemSperm provides kits for in-office sperm preparation and analysis for use with FemaSeed. FemVue is a companion diagnostic for fallopian tube assessment via ultrasound, U.S. FDA-cleared and approved in Europe, the UK, Canada, Japan, Israel, Australia, and New Zealand. FemVue Controlled is a U.S. FDA-cleared diagnostic device that combines features of FemVue and FemChec technologies for multiple clinical uses, including confirming tubal patency before using FemaSeed. FemCerv is an endocervical tissue sampler for cervical cancer diagnosis, U.S. FDA-cleared and approved in Europe, the UK, Canada, Israel, and New Zealand. FemBloc is a permanent birth control solution that involves the minimally-invasive placement of a synthetic tissue adhesive into both fallopian tubes simultaneously, which degrades over time to produce nonfunctional scar tissue for permanent blockage.